Skip to main content

INMUNOTERAPIA ADOPTIVA CON CELULAS T CAR-NG2 PARA LA LEUCEMIA AGUDA CON REORDENAMIENTO MLL

SAF2016-80481-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 31
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

  • Ramos-Muntada, Mireia
  • Trincado Alonso, Juan Luis, 1987-
  • Molina, Oscar
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We applied automated sequential-iFISH coupled with single-cell computational modeling to identify the specific chromosomal gains of the eight typically gained chromosomes in a large cohort of 72 primary diagnostic (DX, n = 62) and matched relapse (REL, n = 10) samples from HHD-B-ALL patients with either favorable or unfavorable clinical outcome in order to characterize the clonal heterogeneity, specific chromosome gains and clonal evolution. Our data show a high degree of clonal heterogeneity and a hierarchical order of chromosome gains in DX samples of HHD-B-ALL. The rates of specific chromosome gains and clonal heterogeneity found in DX samples differ between HHD-B-ALL patients with favorable or unfavorable clinical outcome. In fact, our comprehensive analyses at DX using a computationally defined risk predictor revealed low levels of trisomies +18+10 and low levels of clonal heterogeneity as robust relapse risk factors in minimal residual disease (MRD)-negative childhood HHD-B-ALL patients: relapse-free survival beyond 5 years: 22.1% versus 87.9%, P < 0.0001 and 33.3% versus 80%, P < 0.0001, respectively. Moreover, longitudinal analysis of matched DX-REL HHD-B-ALL samples revealed distinct patterns of clonal evolution at relapse. Our study offers a reliable prognostic sub-stratification of pediatric MRD-negative HHD-B-ALL patients., This work is supported by the Spanish Ministry of Science and Innovation (PID2019-108160RB-I00/AEI/10.13039/501100011033, the European Research Council (CoG-2014-646903), the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R and SAF-2019-108160-R), the Leo Messi Foundation, the Health Institute Carlos III (ISCIII) (RICORS, RD21/0017/0029) within the Next Generation EU program (plan de recuperación, transformación y resilencia), and the Fundación Uno entre Cienmil (PM). Additional funding was provided by the ISCIII (FEDER PI17/01028 and PI20/00822) (CB), the Generalitat de Catalunya (2017/SGR-503) and the Universitat Autònoma de Barcelona (UAB/CF-180034) (JB) and the Blood Cancer UK (CJH). JLT was supported by a Juan de la Cierva fellowship by the Spanish Ministry of Science and Innovation (FJC2019-040868-I), BL-M was supported by the Asociación Española Contra el Cáncer (AECC; INVES20011LÓPE). AB was supported by the Fundación Española de Hematología y Hemoterapia (FEHH). OM was supported by a Beatriu de Pinós Postdoctoral Fellowship (BP2016-00048) from AGAUR (Generalitat de Catalunya), a 2017 Lady Tata Memorial Trust International Award, and the AECC (INVES211226MOLI). PM is an investigator of the Spanish Cell Therapy cooperative network (TERCEL).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Robustness of catalytically dead Cas9 activators in human pluripotent and mesenchymal stem cells

  • Petazzi, Paolo
  • Torres-Ruiz, Raul
  • Fidanza, Antonella
  • Roca-Ho, Heleia
  • Gutierrez-Agüera, Francisco
  • Castaño, Julio
  • Rodríguez-Perales, Sandra
  • Diaz de la Guardia, Rafael
  • López-Millán, Belén
  • Bigas Salvans, Anna
  • Forrester, Lesley M.
  • Bueno, Clara
  • Menéndez, Pablo
Human pluripotent stem cells (hPSCs) and mesenchymal stromal/stem cells (hMSCs) are clinically relevant sources for cellular therapies and for modeling human development and disease. Many stem cell-based applications rely on the ability to activate several endogenous genes simultaneously to modify cell fate. However, genetic intervention of these cells remains challenging. Several catalytically dead Cas9 (dCas9) proteins fused to distinct activation domains can modulate gene expression when directed to their regulatory regions by a specific single-guide RNA (sgRNA). In this study, we have compared the ability of the first-generation dCas9-VP64 activator and the second-generation systems, dCas9-SAM and dCas9-SunTag, to induce gene expression in hPSCs and hMSCs. Several stem cell lines were tested for single and multiplexed gene activation. When the activation of several genes was compared, all three systems induced specific and potent gene expression in both single and multiplexed settings, but the dCas9-SAM and dCas9-SunTag systems resulted in the highest and most consistent level of gene expression. Simultaneous targeting of the same gene with multiple sgRNAs did not result in additive levels of gene expression in hPSCs nor hMSCs. We demonstrate the robustness and specificity of second-generation dCas9 activators as tools to simultaneously activate several endogenous genes in clinically relevant human stem cells., We thank CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for their institutional support. We thank Jose Luis Sardina (IJC, Barcelona) for technical assistance with the teratoma assays. Financial support for this work was obtained from the Catalunya Goverment (SGR330 and PERIS 2017-2019), the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R), the European Research Council (CoG-2014-646903), and the Fundación Leo Messi to P.M.; the Spanish Association against Cancer (AECC-CI-2015) and the Health Institute Carlos III (ISCIII/FEDER, PI17/01028) to C.B.; the Biotechnology and Biological Sciences Research Council (BBRSC) to L.M.F. and A.F.; and the Spanish National Research and Development Plan (ISCIII/FEDER, PI17/02303) and the AEI/MICIU EXPLORA Project (BIO2017-91272-EXP) to S.R.-P. P.M. is an investigator of the Spanish Cell Therapy Cooperative Network (TERCEL). R.T.-R. is supported by a postdoctoral fellowship from the Asociación Española Contra el Cáncer (AECC).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions

  • Bueno, Clara
  • Calero-Nieto, Fernando J.
  • Wang, Xiaonan
  • Valdés-Mas, Rafael
  • Gutiérrez-Agüera, Francisco
  • Roca-Ho, Heleia
  • Ayllon, Verónica
  • Real, Pedro J.
  • Arambilet, David
  • Espinosa Blay, Lluís
  • Torres-Ruiz, Raul
  • Agraz-Doblas, Antonio
  • Varela, Ignacio
  • de Boer, Jasper
  • Bigas Salvans, Anna
  • Gottgens, Bertie
  • Marschalek, Rolf
  • Menéndez, Pablo
The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed in patients with t(4;11)+ B-cell acute lymphoblastic leukemia, but the reciprocal fusion A4M is expressed in only half of the patients. Because prenatal leukemogenesis manifests as impaired early hematopoietic differentiation, we took advantage of well-established human embryonic stem cell-based hematopoietic differentiation models to study whether the A4M fusion cooperates with MA4 during early human hematopoietic development. Co-expression of A4M and MA4 strongly promoted the emergence of hemato-endothelial precursors, both endothelial- and hemogenic-primed. Double fusion-expressing hemato-endothelial precursors specified into significantly higher numbers of both hematopoietic and endothelial-committed cells, irrespective of the differentiation protocol used and without hijacking survival/proliferation. Functional analysis of differentially expressed genes and differentially enriched H3K79me3 genomic regions by RNA-sequencing and H3K79me3 chromatin immunoprecipitation-sequencing, respectively, confirmed a hematopoietic/endothelial cell differentiation signature in double fusion-expressing hemato-endothelial precursors. Importantly, chromatin immunoprecipitation-sequencing analysis revealed a significant enrichment of H3K79 methylated regions specifically associated with HOX-A cluster genes in double fusion-expressing differentiating hematopoietic cells. Overall, these results establish a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic development., Financial support for this work was obtained from the European Research Council (CoG-2014-646903 and PoC-2018-811220) and the Generalitat de Catalunya (SGR330 and PERIS 2017-2019) to PM, the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R and SAF2016-76758-R) to PM and IV, the Spanish Association against Cancer (AECC-CI-2015) and Fero Foudation to CB, the Health Institute Carlos III (ISCIII/FEDER, PI17/01028 and PI17/01028) to CB and PJR, the NIHR GOSH BRC and Great Ormond Street Hospital Children’s Charity to J.dB, and Bloodwise and Cancer Research UK to BG. RM and PM were also supported by the Deutsche José Carreras Leukämie Stiftung. PM also acknowledges financial support from the Obra Social La Caixa-Fundaciò Josep Carreras. R-T-R is supported by a fellowship from the Spanish Association of Cancer Research (AECC). RV-M is supported by a Torres Quevedo fellowship from the Spanish Ministry of Science and Innovation (PTQ-16-08623). P.M is an investigator of the Spanish Cell Therapy cooperative network (TERCEL).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

  • Velasco Hernandez, Talia
  • Beneyto Calabuig, Sergi
  • Velten, Lars
  • Lorden, Patricia
  • Eyras Jiménez, Eduardo
  • Heyn, Holger
  • Menéndez, Pablo
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIFhigh and HIFlow specific AML subgroups (inv(16)/t(8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups. The HIF/hypoxia pathway signature is attenuated in AML-LSCs compared with more differentiated AML cells but is more expressed than in healthy hematopoietic cells. Importantly, chemical inhibition of HIF cooperates with standard-of-care chemotherapy to impair AML growth and to substantially eliminate AML-LSCs in vitro and in vivo. These findings support the HIF pathway in the stem cell-driven drug resistance of AML and unravel avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs., This research was also supported by the Spanish Ministry of Economy and Competitiveness (SAF2016-80481R, PID2019-108160RB-I00/AEI/10.13039/50110011033), “la Caixa” Foundation (LCF/PR/HR19/52160011), the Leo Messi Foundation, “Heroes hasta la médula” initiative, Departament de Recerca i Universitats de la Generalitat de Catalunya (2021 SGR 00887) and ISCIII-RICORS within the Next Generation EU program (plan de recuperación, transformación y resiliencia) to PM and the Health Institute Carlos III (ISCIII/FEDER, PI20/00 822) to Clara Bueno.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors

  • Varela, Ignacio
  • Menéndez, Pablo
  • Sanjuan-Pla, Alejandra
This meeting held at the University of Barcelona in March 2017, brought together scientists and clinicians worldwide to discuss current and future clinico-biological implications of intratumoral heterogeneity (ITH) and subclonal evolution in cancer diagnosis, patient stratification, and treatment resistance in diagnosis, treatment and follow-up. There was consensus that both longitudinal and tumor multi-region studies in matched samples are needed to better understand the dynamics of ITH. The contribution of the epigenome and microenvironment to ITH and subclone evolution remains understudied. It was recommended to combine computational, pathology and imaging tools to study the role of the microenvironment in subclone selection/ evolution., I.V. is funded by Spanish Ministry of Economy and Competitiveness (SAF2016-76758-R), The Fundación Ramón Areces and European Research Council (ERC StG-2014-637904). P.M. is supported by European Research Council (CoG-2014-646903), Spanish Ministry of Economy and Competitiveness (SAF-2016-80481-R & RTC-2016-4603-1), Generalitat de Catalunya (SGR-330) and Obra Social La Caixa-Fundación Josep Carreras. A.S.P. is funded by Ramón & Cajal Program from Spanish Ministry of Economy and Competitiveness (RYC-2015- 17534) and Marie Curie Program from EU (FP7-PEOPLE- 2013-CIG 631171)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions

  • Bueno, Clara
  • Calero-Nieto, Fernando J.
  • Wang, Xiaonan
  • Valdés-Mas, Rafael
  • Gutiérrez-Agüera, Francisco
  • Roca-Ho, Heleia
  • Ayllón, Verónica
  • Real, Pedro J.
  • Arambilet, David
  • Espinosa, Lluis
  • Torres-Ruiz, Raul
  • Agraz-Doblas, Antonio
  • Varela, Ignacio
  • Boer, Jasper de
  • Bigas, Anna
  • Gottgens, Bertie
  • Marschalek, Rolf
  • Menéndez, Pablo
© 2019 Ferrata Storti Foundation., The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed in patients with t(4;11)+ B-cell acute lymphoblastic leukemia, but the reciprocal fusion A4M is expressed in only half of the patients. Because prenatal leukemogenesis manifests as impaired early hematopoietic differentiation, we took advantage of well-established human embryonic stem cell-based hematopoietic differentiation models to study whether the A4M fusion cooperates with MA4 during early human hematopoietic development. Co-expression of A4M and MA4 strongly promoted the emergence of hemato-endothelial precursors, both endothelial- and hemogenic-primed. Double fusion-expressing hemato-endothelial precursors specified into significantly higher numbers of both hematopoietic and endothelial-committed cells, irrespective of the differentiation protocol used and without hijacking survival/proliferation. Functional analysis of differentially expressed genes and differentially enriched H3K79me3 genomic regions by RNA-sequencing and H3K79me3 chromatin immunoprecipitation-sequencing, respectively, confirmed a hematopoietic/endothelial cell differentiation signature in double fusion-expressing hemato-endothelial precursors. Importantly, chromatin immunoprecipitation-sequencing analysis revealed a significant enrichment of H3K79 methylated regions specifically associated with HOX-A cluster genes in double fusion-expressing differentiating hematopoietic cells. Overall, these results establish a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic development., Financial support for this work was obtained from the European Research Council (CoG-2014-646903 and PoC-2018-811220) and the Generalitat de Catalunya (SGR330 and PERIS 2017-2019) to PM, the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R and SAF2016-76758-R) to PM and IV, the Spanish Association against Cancer (AECCCI-2015) and Fero Foudation to CB, the Health Institute Carlos III (ISCIII/FEDER, PI17/01028 and PI17/01028) to CB and PJR, the NIHR GOSH BRC and Great Ormond Street Hospital Children's Charity to J.dB, and Bloodwise and Cancer Research UK to BG. RM and PM were also supported by the Deutsche José Carreras Leukämie Stiftung. PM also acknowledges financial support from the Obra Social La Caixa-Fundaciò Josep Carreras. R-T-R is supported by a fellowship from the Spanish Association of Cancer Research (AECC). RV-M is supported by a Torres Quevedo fellowship from the Spanish Ministry of Science and Innovation (PTQ-16-08623). P.M is an investigator of the Spanish Cell Therapy cooperative network (TERCEL).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity

  • Bueno, Clara
  • Velasco-Hernández, Talia
  • Gutiérrez-Agüera, Francisco
  • Zanetti, Samanta Romina
  • Baroni, Matteo L.
  • Sánchez-Martínez, Diego
  • Molina, Oscar
  • Closa, Adria
  • Agraz-Doblas, Antonio
  • Marín, Pedro
  • Eyras, Eduardo
  • Varela, Ignacio
  • Menéndez, Pablo
© The Author(s) 2019., Chimeric antigen receptors (CARs) have undoubtedly revolutionized immunotherapy, especially in the B-cell acute lymphoblastic leukemia (ALL) arena where over 80% of complete remissions are observed in refractory/relapsed (R/R) B-cell ALL patients treated with CD19-directed CAR T-cells (CARTs) [1]. However, despite holding an unprecedented promise, several issues still have to be resolved before CARTs can be expanded to novel targets and/or malignancies or even provided as first-line treatment in Bcell ALL [2]. For instance, toxicities such as cytokine release syndrome and immune escape mechanisms including loss of the antigen under CART-mediated pressure remain major concerns, urging further research on the mechanisms underlying CARTs cytotoxicity., This work has been supported by the European Research Council (CoG-2014-646903, PoC-2018-811220) to PM, the Spanish Ministry of Economy and Competitiveness (MINECO, SAF-SAF2016-80481-R, BIO2017-85364-R) to PM and EE, the Generalitat de Catalunya (SGR330, SGR102 and PERIS) to PM and EE, the Spanish Association against cancer (AECC-CI-2015) to CB, and the Health Institute Carlos III (ISCIII/FEDER, PI14-01191) to CB. PM also acknowledges financial support from the Obra Social La Caixa-Fundaciò Josep Carreras. SRZ and TV are supported by a Marie Curie fellowships. OM is supported by the Catalan Government through a Beatriu de Pinos fellowship. MB is supported by MINECO through a PhD scholarship. PM is an investigator of the Spanish Cell Therapy cooperative network (TERCEL)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity

  • Zanetti, S.R.
  • Romecin, P.A.
  • Vinyoles, M.
  • Juan, Manel
  • Fuster, José Luis
  • Camós, Mireia
  • Querol, S.
  • Delgado, M.
  • Menéndez, Pablo
BACKGROUND: Although adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells (CD19-CAR T-cells) achieves high rates of complete response in patients with B-cell acute lymphoblastic leukemia (B-ALL), relapse is common. Bone marrow (BM) mesenchymal stem/stromal cells (BM-MSC) are key components of the hematopoietic niche and are implicated in B-ALL pathogenesis and therapy resistance. MSC exert an immunosuppressive effect on T-cells; however, their impact on CD19-CAR T-cell activity is understudied. METHODS: We performed a detailed characterization of BM-MSC from pediatric patients with B-ALL (B-ALL BM-MSC), evaluated their immunomodulatory properties and their impact on CD19-CAR T-cell activity in vitro using microscopy, qRT-PCR, ELISA, flow cytometry analysis and in vivo using a preclinical model of severe colitis and a B-ALL xenograft model. RESULTS: While B-ALL BM-MSC were less proliferative than those from age-matched healthy donors (HD), the morphology, immunophenotype, differentiation potential and chemoprotection was very similar. Likewise, both BM-MSC populations were equally immunosuppressive in vitro and anti-inflammatory in an in vivo model of severe colitis. Interestingly, BM-MSC failed to impair CD19-CAR T-cell cytotoxicity or cytokine production in vitro using B-ALL cell lines and primary B-ALL cells. Finally, the growth of NALM6 cells was controlled in vivo by CD19-CAR T-cells irrespective of the absence/presence of BM-MSC. CONCLUSIONS: Collectively, our data demonstrate that pediatric B-ALL and HD BM-MSC equally immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity., Financial support for this work was obtained from the European Research Council (CoG-2014-646903, PoC-2018-811220), the Spanish Ministry of Economy and Competitiveness (MINECO, SAF2016-80481R), the Fundación Uno entre Cienmil, the Obra Social La Caixa (LCF/PR/HR19/52160011), the Leo Messi Foundation, and the 'Heroes hasta la médula' initiative to PM. SRZ was supported by a Marie Sklodowska Curie Fellowship (GA 795833). MV is supported by a Juan de la Cierva fellowship from the MINECO. PM is an investigator of the Spanish Cell Therapy cooperative network (TERCEL).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bone marrow clonogenic myeloid progenitors from NPM1-mutated AML patients do not harbor the NPM1 mutation: Implication for the cell-of-origin of NPM1+ AML

  • Díaz de la Guardia, Rafael
  • González-Silva, Laura
  • López-Millán, Belén
  • Rodríguez-Sevilla, Juan José
  • Baroni, Matteo L.
  • Bueno, Clara
  • Anguita, Eduardo
  • Vives, Susana
  • Palomo, Laura
  • Lapillonne, Helene
  • Varela, Ignacio
  • Menéndez, Pablo
© 2020 by the authors., The cell-of-origin of NPM1- and FLT3-mutated acute myeloid leukemia (AML) is still a matter of debate. Here, we combined in vitro clonogenic assays with targeted sequencing to gain further insights into the cell-of-origin of NPM1 and FLT3-ITD-mutated AML in diagnostic bone marrow (BM) from nine NPM1+/FLT3-ITD (+/−) AMLs. We reasoned that individually plucked colony forming units (CFUs) are clonal and reflect the progeny of a single stem/progenitor cell. NPM1 and FLT3-ITD mutations seen in the diagnostic blasts were found in only 2/95 and 1/57 individually plucked CFUs, suggesting that BM clonogenic myeloid progenitors in NPM1-mutated and NPM1/FLT3-ITD-mutated AML patients do not harbor such molecular lesions. This supports previous studies on NPM1 mutations as secondary mutations in AML, likely acquired in an expanded pool of committed myeloid progenitors, perhaps CD34−, in line with the CD34−/low phenotype of NPM1-mutated AMLs. This study has important implications on the cell-of-origin of NPM1+ AML, and reinforces that therapeutic targeting of either NPM1 or FLT3-ITD mutations might only have a transient clinical benefit in debulking the leukemia, but is unlikely to be curative since will not target the AML-initiating/preleukemic cells. The absence of NPM1 and FLT3-ITD mutations in normal clonogenic myeloid progenitors is in line with their absence in clonal hematopoiesis of indeterminate potential., We thank CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for their institutional support. Financial support for this work was obtained from the Generalitat de Catalunya (SGR330) to P.M., the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R to P.M. and SAF2016-76758-R to I.V.), the Fundación Uno entre Cienmil, the Obra Social La Caixa (ID 100010434, under agreement LCF/PR/HR19/52160011), the Josep Carreras Foundation, the Leo Messi Foundation, and the Banco Santander Foundation to P.M.; and the Spanish Association against cancer (AECC-CI-2015) to C.B. E.A. acknowledges support form “Fundación Hay Esperanza”. P.M. is an investigator of the Spanish Cell Therapy cooperative network (TERCEL).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope

  • Velasco-Hernández, Talia
  • Zanetti, Samanta Romina
  • Roca-Ho, Heleia
  • Gutiérrez-Agüera, Francisco
  • Petazzi, Paolo
  • Sánchez-Martínez
  • Sánchez-Martínez, Diego
  • Molina, Oscar
  • Baroni, Matteo L.
  • Fuster, José Luis
  • Ballerini, Paola
  • Bueno, Clara
  • Fernández-Fuentes, Narcis
  • Engel, Pablo
  • Menéndez, Pablo
Background There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19 - either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell therapy because they will target both CD22 + CD19 - B-ALL relapses and CD19 - preleukemic cells. However, the immune escape mechanisms from CD22-CAR T cells, and the potential contribution of the epitope binding of the anti-CD22 single-chain variable fragment (scFv) remain understudied. Methods Here, we have developed and comprehensively characterized a novel CD22-CAR (clone hCD22.7) targeting a membrane-distal CD22 epitope and tested its cytotoxic effects against B-ALL cells both in in vitro and in vivo assays. Results Conformational epitope mapping, cross-blocking, and molecular docking assays revealed that the hCD22.7 scFv is a high-affinity binding antibody which specifically binds to the ESTKDGKVP sequence, located in the Ig-like V-type domain, the most distal domain of CD22. We observed efficient killing of B-ALL cells in vitro, although the kinetics were dependent on the level of CD22 expression. Importantly, we show an efficient in vivo control of patients with B-ALL derived xenografts with diverse aggressiveness, coupled to long-term hCD22.7-CAR T cell persistence. Remaining leukemic cells at sacrifice maintained full expression of CD22, ruling out CAR pressure-mediated antigen loss. Finally, the immunogenicity capacity of this hCD22.7-scFv was very similar to that of other CD22 scFv previously used in adoptive T cell therapy. Conclusions We report a novel, high-affinity hCD22.7 scFv which targets a membrane-distal epitope of CD22. 4-1BB-based hCD22.7-CAR T cells efficiently eliminate clinically relevant B- CD22 high and CD22 low ALL primary samples in vitro and in vivo. Our study supports the clinical translation of this hCD22.7-CAR as either single or tandem CD22-CD19-CAR for both naive and anti-CD19-resistant patients with B-ALL., This work was supported by the European Research Council (CoG-2014- 646903, PoC-2018-811220), the Spanish Ministry of Economy and Competitiveness (MINECO-SAF2016-80481-R), the Fundación Uno entre Cienmil, the Obra Social La Caixa (LCF/PR/HR19/52160011), the Spanish Cancer Association and Leo Messi Foundation to PM. CB was supported by the ISCIII/FEDER (PI17/01028). TVH and SRZ were supported by Marie Sklodowska Curie Fellowships (792923 and 795833, respectively). DSM was supported by a Sara Borrell fellowship from the ISCIII. MLB was supported by a FPI scholarship from the MINECO. PM is an investigator of the Spanish Cell Therapy Network (TERCEL).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia

  • Barrios, Oriol de
  • Galaras, Alexandros
  • Trincado, Juan L.
  • Azagra, Alba
  • Collazo, Olga
  • Meler, Ainara
  • Agraz-Doblas, Antonio
  • Bueno, Clara
  • Ballerini, Paola
  • Cazzaniga, Giovanni
  • Stam, Ronald W.
  • Varela, Ignacio
  • Lorenzo, Paola De
  • Grazia Valsecchi, Maria
  • Hatzis, Pantelis
  • Menéndez, Pablo
  • Parra, Maribel
This paper was funded by grants to MP by the Spanish Ministry of Science, Innovation and Universities (SAF2017-87990-R and EUR2019-103835) and elaborated at the Josep Carreras Leukaemia Research Institute (IJC, Badalona, Barcelona) and IDIBELL Research Institute (L’Hospitalet de Llobregat, Barcelona). OdB is funded by a Juan de la Cierva—Formación fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI-2017-32430). AM is funded by the Spanish Ministry of Science, Innovation and Universities, which is part of the Agencia Estatal de Investigación (AEI), through grant PRE2018-083183 (cofunded by the European Social Fund). Work in PM and CB’s lab was supported by the European Research Council (CoG-2014646903), the Spanish Ministry of Economy and Competitiveness (SAF-2016-80481-R), Uno entre Cien Mil Foundation, the Leo Messi Foundation, the Asociación Española Contra el Cáncer (AECC-CI-2015), and the ISCIII/FEDER (PI17/01028). ¡
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

  • Bueno, Clara
  • Barrera, Susana
  • Bataller, Alex
  • Ortiz-Maldonado, Valentín
  • Elliot, Natalina
  • O’Byrne, Sorcha
  • Wang, Guanlin
  • Rovira, Montserrat
  • Gutierrez-Aguera, Francisco
  • Trincado, Juan L.
  • González-González, María
  • Morgades, Mireia
  • Sorigué, Marc
  • Bárcena, Paloma
  • Zanetti, Samanta Romina
  • Torrebadell, Montse
  • Vega-García, Nerea
  • Rives, Susana
  • Mallo, Mar
  • Solé, Francesc
  • Mead, Adam J.
  • Roberts, Irene
  • Thongjuea, Supat
  • Psaila, Bethan
  • Juan, Manel
  • Delgado, Julio
  • Urbano-Ispizúa, Álvaro
  • Ribera, Josep-Maria
  • Orfao, Alberto
  • Roy, Anindita
  • Menéndez, Pablo
CD19-directed immunotherapies have revolutionized the treatment of advanced B-cell acute lymphoblastic leukemia (B-ALL). Despite initial impressive rates of complete remission (CR) many patients ultimately relapse. Patients with B-ALL successfully treated with CD19-directed T cells eventually relapse, which, coupled with the early onset of CD22 expression during B-cell development, suggests that preexisting CD34+CD22+CD19− (pre)-leukemic cells represent an “early progenitor origin-related” mechanism underlying phenotypic escape to CD19-directed immunotherapies. We demonstrate that CD22 expression precedes CD19 expression during B-cell development. CD34+CD19−CD22+ cells are found in diagnostic and relapsed bone marrow samples of ∼70% of patients with B-ALL, and their frequency increases twofold in patients with B-ALL in CR after CD19 CAR T-cell therapy. The median of CD34+CD19−CD22+ cells before treatment was threefold higher in patients in whom B-ALL relapsed after CD19-directed immunotherapy (median follow-up, 24 months). Fluorescence in situ hybridization analysis in flow-sorted cell populations and xenograft modeling revealed that CD34+CD19−CD22+ cells harbor the genetic abnormalities present at diagnosis and initiate leukemogenesis in vivo. Our data suggest that preleukemic CD34+CD19−CD22+ progenitors underlie phenotypic escape after CD19-directed immunotherapies and reinforce ongoing clinical studies aimed at CD19/CD22 dual targeting as a strategy for reducing CD19− relapses. The implementation of CD34/CD19/CD22 immunophenotyping in clinical laboratories for initial diagnosis and subsequent monitoring of patients with B-ALL during CD19-targeted therapy is encouraged., The work in P.M. and C.B.’s Laboratory was supported by the European Research Council (CoG-2014-646903, PoC-2018-811220) and the Spanish Ministry of Economy and Competitiveness (SAF2016-80481R, PID2019-108160RB-I00) (P.M.); the ISCIII (ISCIII/FEDER, PI17/01028 and PI20/00822), the Spanish Association against Cancer (AECC), and the FERO Foundation (C.B.). P.M. and J.M.R. acknowledge the support of ISCIII-RICORS within the Next Generation EU program (Plan de Recuperación, Transformación y Resiliencia). N.E. is supported by Cancer Research UK and a Children and Young People’s Cancer Innovation Award (DRCPGM\100058). A.R. is supported by a Wellcome Trust Clinical Research Career Development Fellowship (216632/Z/19/Z). A.O. was supported by ISCIII (PI19/011183). F.S. was supported by AGAUR/Generalitat de Catalunya (SGR288). The single-cell transcriptomic analysis was supported by MRC Discovery award MRCDA 0816-11 and the MRC WIMM Single Cell Facility and MRC-funded Oxford Consortium for Single-Cell Biology (MR/M00919X/1) provided assistance., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia

  • Sánchez-Martínez, Diego
  • Baroni, Matteo L.
  • Gutierrez-Agüera, Francisco
  • Roca-Ho, Heleia
  • Blanch-Lombarte, Oscar
  • González-García, Sara
  • Torrebadell, Montserrat
  • Junca, Jordi
  • Ramírez-Orellana, Manuel
  • Velasco-Hernández, Talía
  • Bueno, Clara
  • Fuster, José Luís
  • Prado, Julia G.
  • Calvo, Julien
  • Uzan, Benjamin
  • Cools, Jan
  • Camos, Mireia
  • Pflumio, Françoise
  • Toribio, María Luisa
  • Menéndez, Pablo
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor (CAR) T cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CART fratricide. CD1a is exclusively expressed in cortical T-ALL (coT-ALL), a major subset of T-ALL, and retained at relapse. This article reports that the expression of CD1a is mainly restricted to developing cortical thymocytes, and neither CD34+ progenitors nor T cells express CD1a during ontogeny, confining the risk of on-target/off-tumor toxicity. We thus developed and preclinically validated a CD1a-specific CAR with robust and specific cytotoxicity in vitro and antileukemic activity in vivo in xenograft models of coT-ALL, using both cell lines and coT-ALL patient–derived primary blasts. CD1a-CARTs are fratricide resistant, persist long term in vivo (retaining antileukemic activity in re-challenge experiments), and respond to viral antigens. Our data support the therapeutic and safe use of fratricide-resistant CD1a-CARTs for relapsed/refractory coT-ALL., This research was supported by the European Research Council (H2020) (CoG-2014-646903), the Agencia Estatal de Investigacion/European Re- ´ gional Development Fund (SAF2016-80481-R and SAF2016-75442-R), and the Catalunya Government (SGR330 and PERIS 2017) (P.M.), as well as the Asociacion Española Contra el C ´ ancer, Beca FERO, and the ´ ISCIII/FEDER (PI17/01028) (C.B.). P.M. also acknowledges institutional support from the Obra Social La Caixa-Fundacio Josep Carreras. J.G.P. ` holds a Miguel Servet contract (CP15/00014), and O.B.-L. is supported by an AGAUR-FI fellowship from the Catalan Government. P.M. is an investigator of the Spanish Cell Therapy cooperative network (TERCEL)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impaired condensin complex and Aurora B kinase underlie mitotic and chromosomal defects in hyperdiploid B-cell ALL

  • Molina, Oscar
  • Vinyoles, Meritxell
  • Granada, Isabel
  • Roca-Ho, Heleia
  • Gutierrez-Agüera, Francisco
  • Valledor, Luis
  • López-López, Carlos M.
  • Rodríguez-González, Pablo
  • Trincado, Juan L.
  • Menéndez, Sofía T.
  • Pal, Deepali
  • Ballerini, Paola
  • den Boer, Monique L.
  • Plensa, Isabel
  • Mar Perez-Iribarne, M.
  • Rodríguez-Perales, Sandra
  • Calasanz, María José
  • Ramírez-Orellana, Manuel
  • Rodríguez, René
  • Camós, Mireia
  • Calvo, Maria V.
  • Bueno, Clara
  • Menéndez, Pablo
B-cell acute lymphoblastic leukemia (ALL; B-ALL) is the most common pediatric cancer, and high hyperdiploidy (HyperD) identifies the most common subtype of pediatric B-ALL. Despite HyperD being an initiating oncogenic event affiliated with childhood B-ALL, the mitotic and chromosomal defects associated with HyperD B-ALL (HyperD-ALL) remain poorly characterized. Here, we have used 54 primary pediatric B-ALL samples to characterize the cellular-molecular mechanisms underlying the mitotic/chromosome defects predicated to be early pathogenic contributors in HyperD-ALL. We report that HyperD-ALL blasts are low proliferative and show a delay in early mitosis at prometaphase, associated with chromosome-alignment defects at the metaphase plate leading to robust chromosome-segregation defects and nonmodal karyotypes. Mechanistically, biochemical, functional, and mass-spectrometry assays revealed that condensin complex is impaired in HyperD-ALL cells, leading to chromosome hypocondensation, loss of centromere stiffness, and mislocalization of the chromosome passenger complex proteins Aurora B kinase (AURKB) and Survivin in early mitosis. HyperD-ALL cells show chromatid cohesion defects and an impaired spindle assembly checkpoint (SAC), thus undergoing mitotic slippage due to defective AURKB and impaired SAC activity, downstream of condensin complex defects. Chromosome structure/condensation defects and hyperdiploidy were reproduced in healthy CD34+ stem/progenitor cells upon inhibition of AURKB and/or SAC. Collectively, hyperdiploid B-ALL is associated with a defective condensin complex, AURKB, and SAC., This work was supported by the European Research Council (CoG-2014-646903 [P.M.]), the Spanish Ministry of Economy and Competitiveness (SAF-2016-80481-R [P.M.]), the Asociación Española Contra el Cáncer (AECC-CI-2015), and the ISCIII (PI17/01028) (C.B.). The authors also acknowledge support from Fundación Leo Messi and the Fundación Uno entre Cienmil. O.M. was supported by a Lady Tata Memorial Trust (2017) and a “Beatriu de Pinós” postdoctoral fellowship (2018-2019) from Generalitat de Catalunya. D.P. was supported by an NC3Rs fellowship and a Children’s Cancer and Leukemia Group (CCLG) project grant. This work was also supported by the Spanish Ministry of Economy and Competitiveness (SAF-2016-75286-R [R.R.]), the ISCIII/FEDER (Miguel Servet Program CPII16/00049 [R.R.], Sara Borrell Program CD16/00103 [S.T.M.], and PI16/00280), and Consorcio CIBERONC (CB16/12/00390)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

  • Ramos-Muntada, Mireia
  • Trincado Alonso, Juan Luis, 1987-
  • Molina, Oscar
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We applied automated sequential-iFISH coupled with single-cell computational modeling to identify the specific chromosomal gains of the eight typically gained chromosomes in a large cohort of 72 primary diagnostic (DX, n = 62) and matched relapse (REL, n = 10) samples from HHD-B-ALL patients with either favorable or unfavorable clinical outcome in order to characterize the clonal heterogeneity, specific chromosome gains and clonal evolution. Our data show a high degree of clonal heterogeneity and a hierarchical order of chromosome gains in DX samples of HHD-B-ALL. The rates of specific chromosome gains and clonal heterogeneity found in DX samples differ between HHD-B-ALL patients with favorable or unfavorable clinical outcome. In fact, our comprehensive analyses at DX using a computationally defined risk predictor revealed low levels of trisomies +18+10 and low levels of clonal heterogeneity as robust relapse risk factors in minimal residual disease (MRD)-negative childhood HHD-B-ALL patients: relapse-free survival beyond 5 years: 22.1% versus 87.9%, P < 0.0001 and 33.3% versus 80%, P < 0.0001, respectively. Moreover, longitudinal analysis of matched DX-REL HHD-B-ALL samples revealed distinct patterns of clonal evolution at relapse. Our study offers a reliable prognostic sub-stratification of pediatric MRD-negative HHD-B-ALL patients., This work is supported by the Spanish Ministry of Science and Innovation (PID2019-108160RB-I00/AEI/10.13039/501100011033, the European Research Council (CoG-2014-646903), the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R and SAF-2019-108160-R), the Leo Messi Foundation, the Health Institute Carlos III (ISCIII) (RICORS, RD21/0017/0029) within the Next Generation EU program (plan de recuperación, transformación y resilencia), and the Fundación Uno entre Cienmil (PM). Additional funding was provided by the ISCIII (FEDER PI17/01028 and PI20/00822) (CB), the Generalitat de Catalunya (2017/SGR-503) and the Universitat Autònoma de Barcelona (UAB/CF-180034) (JB) and the Blood Cancer UK (CJH). JLT was supported by a Juan de la Cierva fellowship by the Spanish Ministry of Science and Innovation (FJC2019-040868-I), BL-M was supported by the Asociación Española Contra el Cáncer (AECC; INVES20011LÓPE). AB was supported by the Fundación Española de Hematología y Hemoterapia (FEHH). OM was supported by a Beatriu de Pinós Postdoctoral Fellowship (BP2016-00048) from AGAUR (Generalitat de Catalunya), a 2017 Lady Tata Memorial Trust International Award, and the AECC (INVES211226MOLI). PM is an investigator of the Spanish Cell Therapy cooperative network (TERCEL).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Robustness of catalytically dead Cas9 activators in human pluripotent and mesenchymal stem cells

  • Petazzi, Paolo
  • Torres-Ruiz, Raul
  • Fidanza, Antonella
  • Roca-Ho, Heleia
  • Gutierrez-Agüera, Francisco
  • Castaño, Julio
  • Rodríguez-Perales, Sandra
  • Diaz de la Guardia, Rafael
  • López-Millán, Belén
  • Bigas Salvans, Anna
  • Forrester, Lesley M.
  • Bueno, Clara
  • Menéndez, Pablo
Human pluripotent stem cells (hPSCs) and mesenchymal stromal/stem cells (hMSCs) are clinically relevant sources for cellular therapies and for modeling human development and disease. Many stem cell-based applications rely on the ability to activate several endogenous genes simultaneously to modify cell fate. However, genetic intervention of these cells remains challenging. Several catalytically dead Cas9 (dCas9) proteins fused to distinct activation domains can modulate gene expression when directed to their regulatory regions by a specific single-guide RNA (sgRNA). In this study, we have compared the ability of the first-generation dCas9-VP64 activator and the second-generation systems, dCas9-SAM and dCas9-SunTag, to induce gene expression in hPSCs and hMSCs. Several stem cell lines were tested for single and multiplexed gene activation. When the activation of several genes was compared, all three systems induced specific and potent gene expression in both single and multiplexed settings, but the dCas9-SAM and dCas9-SunTag systems resulted in the highest and most consistent level of gene expression. Simultaneous targeting of the same gene with multiple sgRNAs did not result in additive levels of gene expression in hPSCs nor hMSCs. We demonstrate the robustness and specificity of second-generation dCas9 activators as tools to simultaneously activate several endogenous genes in clinically relevant human stem cells., We thank CERCA/Generalitat de Catalunya and Fundació Josep Carreras-Obra Social la Caixa for their institutional support. We thank Jose Luis Sardina (IJC, Barcelona) for technical assistance with the teratoma assays. Financial support for this work was obtained from the Catalunya Goverment (SGR330 and PERIS 2017-2019), the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R), the European Research Council (CoG-2014-646903), and the Fundación Leo Messi to P.M.; the Spanish Association against Cancer (AECC-CI-2015) and the Health Institute Carlos III (ISCIII/FEDER, PI17/01028) to C.B.; the Biotechnology and Biological Sciences Research Council (BBRSC) to L.M.F. and A.F.; and the Spanish National Research and Development Plan (ISCIII/FEDER, PI17/02303) and the AEI/MICIU EXPLORA Project (BIO2017-91272-EXP) to S.R.-P. P.M. is an investigator of the Spanish Cell Therapy Cooperative Network (TERCEL). R.T.-R. is supported by a postdoctoral fellowship from the Asociación Española Contra el Cáncer (AECC).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions

  • Bueno, Clara
  • Calero-Nieto, Fernando J.
  • Wang, Xiaonan
  • Valdés-Mas, Rafael
  • Gutiérrez-Agüera, Francisco
  • Roca-Ho, Heleia
  • Ayllon, Verónica
  • Real, Pedro J.
  • Arambilet, David
  • Espinosa Blay, Lluís
  • Torres-Ruiz, Raul
  • Agraz-Doblas, Antonio
  • Varela, Ignacio
  • de Boer, Jasper
  • Bigas Salvans, Anna
  • Gottgens, Bertie
  • Marschalek, Rolf
  • Menéndez, Pablo
The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed in patients with t(4;11)+ B-cell acute lymphoblastic leukemia, but the reciprocal fusion A4M is expressed in only half of the patients. Because prenatal leukemogenesis manifests as impaired early hematopoietic differentiation, we took advantage of well-established human embryonic stem cell-based hematopoietic differentiation models to study whether the A4M fusion cooperates with MA4 during early human hematopoietic development. Co-expression of A4M and MA4 strongly promoted the emergence of hemato-endothelial precursors, both endothelial- and hemogenic-primed. Double fusion-expressing hemato-endothelial precursors specified into significantly higher numbers of both hematopoietic and endothelial-committed cells, irrespective of the differentiation protocol used and without hijacking survival/proliferation. Functional analysis of differentially expressed genes and differentially enriched H3K79me3 genomic regions by RNA-sequencing and H3K79me3 chromatin immunoprecipitation-sequencing, respectively, confirmed a hematopoietic/endothelial cell differentiation signature in double fusion-expressing hemato-endothelial precursors. Importantly, chromatin immunoprecipitation-sequencing analysis revealed a significant enrichment of H3K79 methylated regions specifically associated with HOX-A cluster genes in double fusion-expressing differentiating hematopoietic cells. Overall, these results establish a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic development., Financial support for this work was obtained from the European Research Council (CoG-2014-646903 and PoC-2018-811220) and the Generalitat de Catalunya (SGR330 and PERIS 2017-2019) to PM, the Spanish Ministry of Economy and Competitiveness (SAF2016-80481-R and SAF2016-76758-R) to PM and IV, the Spanish Association against Cancer (AECC-CI-2015) and Fero Foudation to CB, the Health Institute Carlos III (ISCIII/FEDER, PI17/01028 and PI17/01028) to CB and PJR, the NIHR GOSH BRC and Great Ormond Street Hospital Children’s Charity to J.dB, and Bloodwise and Cancer Research UK to BG. RM and PM were also supported by the Deutsche José Carreras Leukämie Stiftung. PM also acknowledges financial support from the Obra Social La Caixa-Fundaciò Josep Carreras. R-T-R is supported by a fellowship from the Spanish Association of Cancer Research (AECC). RV-M is supported by a Torres Quevedo fellowship from the Spanish Ministry of Science and Innovation (PTQ-16-08623). P.M is an investigator of the Spanish Cell Therapy cooperative network (TERCEL).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

  • Velasco Hernandez, Talia
  • Beneyto Calabuig, Sergi
  • Velten, Lars
  • Lorden, Patricia
  • Eyras Jiménez, Eduardo
  • Heyn, Holger
  • Menéndez, Pablo
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIFhigh and HIFlow specific AML subgroups (inv(16)/t(8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups. The HIF/hypoxia pathway signature is attenuated in AML-LSCs compared with more differentiated AML cells but is more expressed than in healthy hematopoietic cells. Importantly, chemical inhibition of HIF cooperates with standard-of-care chemotherapy to impair AML growth and to substantially eliminate AML-LSCs in vitro and in vivo. These findings support the HIF pathway in the stem cell-driven drug resistance of AML and unravel avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs., This research was also supported by the Spanish Ministry of Economy and Competitiveness (SAF2016-80481R, PID2019-108160RB-I00/AEI/10.13039/50110011033), “la Caixa” Foundation (LCF/PR/HR19/52160011), the Leo Messi Foundation, “Heroes hasta la médula” initiative, Departament de Recerca i Universitats de la Generalitat de Catalunya (2021 SGR 00887) and ISCIII-RICORS within the Next Generation EU program (plan de recuperación, transformación y resiliencia) to PM and the Health Institute Carlos III (ISCIII/FEDER, PI20/00 822) to Clara Bueno.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells

  • Godfrey, Laura|||0000-0002-6222-3563
  • Crump, Nicholas|||0000-0001-9610-6763
  • O'Byrne, Sorcha|||0000-0002-3116-1646
  • Lau, I. Jun
  • Rice, Siobhan
  • Harman, Joe R.
  • Jackson, Thomas
  • Elliott, Natalina|||0000-0002-6713-7349
  • Buck, Gemma
  • Connor, Christopher
  • Thorne, Ross
  • Knapp, David J. H. F.
  • Heidenreich, Olaf|||0000-0001-5404-6483
  • Vyas, Paresh
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Inglott, Sara
  • Ancliff, Philip
  • Geng, Huimin
  • Roberts, Irene|||0000-0002-6094-6397
  • Roy, Anindita
  • Milne, Thomas|||0000-0002-0413-4271
MLL gene rearrangements (MLLr) are a common cause of aggressive, incurable acute lymphoblastic leukemias (ALL) in infants and children, most of which originate in utero. The most common MLLr produces an MLL-AF4 fusion protein. MLL-AF4 promotes leukemogenesis by activating key target genes, mainly through recruitment of DOT1L and increased histone H3 lysine-79 methylation (H3K79me2/3). One key MLL-AF4 target gene is PROM1, which encodes CD133 (Prominin-1). CD133 is a pentaspan transmembrane glycoprotein that represents a potential pan-cancer target as it is found on multiple cancer stem cells. Here we demonstrate that aberrant PROM1/CD133 expression is essential for leukemic cell growth, mediated by direct binding of MLL-AF4. Activation is controlled by an intragenic H3K79me2/3 enhancer element (KEE) leading to increased enhancer-promoter interactions between PROM1 and the nearby gene TAPT1. This dual locus regulation is reflected in a strong correlation of expression in leukemia. We find that in PROM1/CD133 non-expressing cells, the PROM1 locus is repressed by polycomb repressive complex 2 (PRC2) binding, associated with reduced expression of TAPT1, partially due to loss of interactions with the PROM1 locus. Together, these results provide the first detailed analysis of PROM1/CD133 regulation that explains CD133 expression in MLLr ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Aneuploidy in Cancer, Lessons from Acute Lymphoblastic Leukemia

  • Molina, Oscar|||0000-0001-7585-4519
  • Abad, Maria Alba|||0000-0002-8816-1524
  • Sole, F.|||0000-0002-3251-2161
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Aneuploidy, the gain or loss of chromosomes in a cell, is a hallmark of cancer. Although our understanding of the contribution of aneuploidy to cancer initiation and progression is incomplete, significant progress has been made in uncovering the cellular consequences of aneuploidy and how aneuploid cancer cells self-adapt to promote tumorigenesis. Aneuploidy is physiologically associated with significant cellular stress but, paradoxically, it favors tumor progression. Although more common in solid tumors, different forms of aneuploidy represent the initiating oncogenic lesion in patients with B cell acute lymphoblastic leukemia (B-ALL), making B-ALL an excellent model for studying the role of aneuploidy in tumorigenesis. We review the molecular mechanisms underlying aneuploidy and discuss its contributions to B-ALL initiation and progression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bone marrow clonogenic myeloid progenitors from NPM1-mutated AML patients do not harbor the NPM1 mutation, Implication for the cell-of-origin of NPM1+ AML

  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • González-silva, L.
  • López-Millán, Belén|||0000-0002-9757-5454
  • Rodriguez-Sevilla, Juan Jose|||0000-0002-4741-7925
  • Baroni, Matteo Libero|||0000-0001-8265-2050
  • Bueno, Clara|||0000-0003-1442-6216
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • Lapillonne, Hélène|||0000-0002-6900-8313
  • Varela, Ignacio|||0000-0002-0969-506X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
The cell-of-origin of NPM1- and FLT3-mutated acute myeloid leukemia (AML) is still a matter of debate. Here, we combined in vitro clonogenic assays with targeted sequencing to gain further insights into the cell-of-origin of NPM1 and FLT3-ITD-mutated AML in diagnostic bone marrow (BM) from nine NPM1+/FLT3-ITD (+/-) AMLs. We reasoned that individually plucked colony forming units (CFUs) are clonal and reflect the progeny of a single stem/progenitor cell. NPM1 and FLT3-ITD mutations seen in the diagnostic blasts were found in only 2/95 and 1/57 individually plucked CFUs, suggesting that BM clonogenic myeloid progenitors in NPM1-mutated and NPM1/FLT3-ITD-mutated AML patients do not harbor such molecular lesions. This supports previous studies on NPM1 mutations as secondary mutations in AML, likely acquired in an expanded pool of committed myeloid progenitors, perhaps CD34-, in line with the CD34 phenotype of NPM1-mutated AMLs. This study has important implications on the cell-of-origin of NPM1+ AML, and reinforces that therapeutic targeting of either NPM1 or FLT3-ITD mutations might only have a transient clinical benefit in debulking the leukemia, but is unlikely to be curative since will not target the AML-initiating/preleukemic cells. The absence of NPM1 and FLT3-ITD mutations in normal clonogenic myeloid progenitors is in line with their absence in clonal hematopoiesis of indeterminate potential.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells

  • Petazzi, Paolo|||0000-0002-1036-2895
  • Torres, Raul|||0000-0001-9606-0398
  • Fidanza, Andrea|||0000-0001-7766-0806
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • López-Millán, Belén|||0000-0002-9757-5454
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Forrester, L. M.
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Human pluripotent stem cells (hPSCs) and mesenchymal stromal/stem cells (hMSCs) are clinically relevant sources for cellular therapies and for modeling human development and disease. Many stem cell-based applications rely on the ability to activate several endogenous genes simultaneously to modify cell fate. However, genetic intervention of these cells remains challenging. Several catalytically dead Cas9 (dCas9) proteins fused to distinct activation domains can modulate gene expression when directed to their regulatory regions by a specific single-guide RNA (sgRNA). In this study, we have compared the ability of the first-generation dCas9-VP64 activator and the second-generation systems, dCas9-SAM and dCas9-SunTag, to induce gene expression in hPSCs and hMSCs. Several stem cell lines were tested for single and multiplexed gene activation. When the activation of several genes was compared, all three systems induced specific and potent gene expression in both single and multiplexed settings, but the dCas9-SAM and dCas9-SunTag systems resulted in the highest and most consistent level of gene expression. Simultaneous targeting of the same gene with multiple sgRNAs did not result in additive levels of gene expression in hPSCs nor hMSCs. We demonstrate the robustness and specificity of second-generation dCas9 activators as tools to simultaneously activate several endogenous genes in clinically relevant human stem cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

  • Libero Baroni, Matteo
  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Castellà, Maria
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Lapillone, Helene
  • Bras, Anne E.
  • Van Der Velden, Vincent H. J.
  • Junca, Jordi|||0000-0003-0142-772X
  • Marin, Pedro
  • Bataller, Alex|||0000-0002-6085-2745
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Vick, Binje
  • Jeremias, Irmela|||0000-0003-1773-7677
  • Lopez, Angel
  • Sorigue, Marc|||0000-0002-0587-591X
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. Chimeric antigen receptor T-cell (CART) immunotherapies for patients with refractory or relapse (R/R) AML are challenging because of the absence of a universal pan-AML target antigen and the shared expression of target antigens with normal hematopoietic stem/progenitor cells (HSPCs), which may lead to life-threating on-target/off-tumor cytotoxicity. CD33-redirected and CD123-redirected CARTs for AML are in advanced preclinical and clinical development, and they exhibit robust antileukemic activity. However, preclinical and clinical controversy exists on whether such CARTs are myeloablative. METHODS: We set out to comparatively characterize in vitro and in vivo the efficacy and safety of 41BB-based and CD28-based CARCD123. We analyzed 97 diagnostic and relapse AML primary samples to investigate whether CD123 is a suitable immunotherapeutic target, and we used several xenograft models and in vitro assays to assess the myeloablative potential of our second-generation CD123 CARTs. RESULTS: Here, we show that CD123 represents a bona fide target for AML and show that both 41BB-based and CD28-based CD123 CARTs are very efficient in eliminating both AML cell lines and primary cells in vitro and in vivo. However, both 41BB-based and CD28-based CD123 CARTs ablate normal human hematopoiesis and prevent the establishment of de novo hematopoietic reconstitution by targeting both immature and myeloid HSPCs. CONCLUSIONS: This study calls for caution when clinically implementing CD123 CARTs, encouraging its preferential use as a bridge to allo-HSCT in patients with R/R AML.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope

  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Molina, Oscar|||0000-0001-7585-4519
  • Baroni, Matteo Libero|||0000-0001-8265-2050
  • Fuster, José Luis|||0000-0002-4881-9440
  • Ballerini, Paola
  • Bueno, Clara|||0000-0003-1442-6216
  • Fernández-Fuentes, Narcís
  • Engel, Pablo|||0000-0001-8410-252X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Background There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19 - either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell therapy because they will target both CD22 + CD19 - B-ALL relapses and CD19 - preleukemic cells. However, the immune escape mechanisms from CD22-CAR T cells, and the potential contribution of the epitope binding of the anti-CD22 single-chain variable fragment (scFv) remain understudied. Methods Here, we have developed and comprehensively characterized a novel CD22-CAR (clone hCD22.7) targeting a membrane-distal CD22 epitope and tested its cytotoxic effects against B-ALL cells both in in vitro and in vivo assays. Results Conformational epitope mapping, cross-blocking, and molecular docking assays revealed that the hCD22.7 scFv is a high-affinity binding antibody which specifically binds to the ESTKDGKVP sequence, located in the Ig-like V-type domain, the most distal domain of CD22. We observed efficient killing of B-ALL cells in vitro, although the kinetics were dependent on the level of CD22 expression. Importantly, we show an efficient in vivo control of patients with B-ALL derived xenografts with diverse aggressiveness, coupled to long-term hCD22.7-CAR T cell persistence. Remaining leukemic cells at sacrifice maintained full expression of CD22, ruling out CAR pressure-mediated antigen loss. Finally, the immunogenicity capacity of this hCD22.7-scFv was very similar to that of other CD22 scFv previously used in adoptive T cell therapy. Conclusions We report a novel, high-affinity hCD22.7 scFv which targets a membrane-distal epitope of CD22. 4-1BB-based hCD22.7-CAR T cells efficiently eliminate clinically relevant B- CD22 high and CD22 low ALL primary samples in vitro and in vivo. Our study supports the clinical translation of this hCD22.7-CAR as either single or tandem CD22-CD19-CAR for both naive and anti-CD19-resistant patients with B-ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity

  • Zanetti, S. R.|||0000-0002-9052-8751
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Juan, Manel|||0000-0002-3064-1648
  • Fuster, José Luis|||0000-0002-4881-9440
  • Camós, Mireia|||0000-0003-3658-7942
  • Querol, Sergi|||0000-0002-1105-8633
  • Delgado, M.
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Background Although adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells (CD19-CAR T-cells) achieves high rates of complete response in patients with B-cell acute lymphoblastic leukemia (B-ALL), relapse is common. Bone marrow (BM) mesenchymal stem/stromal cells (BM-MSC) are key components of the hematopoietic niche and are implicated in B-ALL pathogenesis and therapy resistance. MSC exert an immunosuppressive effect on T-cells; however, their impact on CD19-CAR T-cell activity is understudied. Methods We performed a detailed characterization of BM-MSC from pediatric patients with B-ALL (B-ALL BM-MSC), evaluated their immunomodulatory properties and their impact on CD19-CAR T-cell activity in vitro using microscopy, qRT-PCR, ELISA, flow cytometry analysis and in vivo using a preclinical model of severe colitis and a B-ALL xenograft model. Results While B-ALL BM-MSC were less proliferative than those from age-matched healthy donors (HD), the morphology, immunophenotype, differentiation potential and chemoprotection was very similar. Likewise, both BM-MSC populations were equally immunosuppressive in vitro and anti-inflammatory in an in vivo model of severe colitis. Interestingly, BM-MSC failed to impair CD19-CAR T-cell cytotoxicity or cytokine production in vitro using B-ALL cell lines and primary B-ALL cells. Finally, the growth of NALM6 cells was controlled in vivo by CD19-CAR T-cells irrespective of the absence/presence of BM-MSC. Conclusions Collectively, our data demonstrate that pediatric B-ALL and HD BM-MSC equally immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions

  • Bueno, Clara|||0000-0003-1442-6216
  • Calero-Nieto, Fernando|||0000-0003-3358-8253
  • Wang, X.
  • Valdés-Mas, Rafael
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Ayllon, Veronica
  • Real, P. J.
  • Arambilet Mobilla, David|||0000-0001-7372-0082
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Torres, Raul|||0000-0001-9606-0398
  • Agraz-Doblás, Antonio|||0000-0003-1307-4175
  • Varela, Ignacio|||0000-0002-0969-506X
  • De Boer, J.
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Gottgens, B.
  • Marschalek, Rolf|||0000-0003-4870-3445
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed in patients with t(4;11)+ B-cell acute lymphoblastic leukemia, but the reciprocal fusion A4M is expressed in only half of the patients. Because prenatal leukemogenesis manifests as impaired early hematopoietic differentiation, we took advantage of well-established human embryonic stem cell-based hematopoietic differentiation models to study whether the A4M fusion cooperates with MA4 during early human hematopoietic development. Co-expression of A4M and MA4 strongly promoted the emergence of hemato-endothelial precursors, both endothelial- and hemogenic-primed. Double fusionexpressing hemato-endothelial precursors specified into significantly higher numbers of both hematopoietic and endothelial-committed cells, irrespective of the differentiation protocol used and without hijacking survival/proliferation. Functional analysis of differentially expressed genes and differentially enriched H3K79me3 genomic regions by RNA-sequencing and H3K79me3 chromatin immunoprecipitation-sequencing, respectively, confirmed a hematopoietic/endothelial cell differentiation signature in double fusion-expressing hemato-endothelial precursors. Importantly, chromatin immunoprecipitation-sequencing analysis revealed a significant enrichment of H3K79 methylated regions specifically associated with HOX-A cluster genes in double fusion-expressing differentiating hematopoietic cells. Overall, these results establish a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CD133-directed CAR T-cells for MLL leukemia, on-target, off-tumor myeloablative toxicity

  • Bueno, Clara|||0000-0003-1442-6216
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Baroni, Matteo Libero|||0000-0001-8265-2050
  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Molina, Oscar|||0000-0001-7585-4519
  • Closa, Adria|||0000-0002-9302-337X
  • Agraz-Doblás, Antonio|||0000-0003-1307-4175
  • Marin, Pedro
  • Eyras, Eduardo|||0000-0003-0793-6218
  • Varela, Ignacio|||0000-0002-0969-506X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing

  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Palomo, Marta|||0000-0002-3261-6577
  • Tirado, Néstor
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Juan, Manel|||0000-0002-3064-1648
  • Carlet, Michela
  • Jeremias, Irmela|||0000-0003-1773-7677
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
CD19-directed chimeric antigen receptors (CAR) T cells induce impressive rates of complete response in advanced B-cell malignancies, specially in B-cell acute lymphoblastic leukemia (B-ALL). However, CAR T-cell-treated patients eventually progress due to poor CAR T-cell persistence and/or disease relapse. The bone marrow (BM) is the primary location for acute leukemia. The rapid/efficient colonization of the BM by systemically infused CD19-CAR T cells might enhance CAR T-cell activity and persistence, thus, offering clinical benefits. Circulating cells traffic to BM upon binding of tetrasaccharide sialyl-Lewis X (sLeX)-decorated E-selectin ligands (sialofucosylated) to the E-selectin receptor expressed in the vascular endothelium. sLeX-installation in E-selectin ligands is achieved through an ex vivo fucosylation reaction. Here, we sought to characterize the basal and cell-autonomous display of sLeX in CAR T-cells activated using different cytokines, and to assess whether exofucosylation of E-selectin ligands improves CD19-CAR T-cell activity and BM homing. We report that cell-autonomous sialofucosylation (sLeX display) steadily increases in culture- and in vivo -expanded CAR T cells, and that, the cytokines used during T-cell activation influence both the degree of such endogenous sialofucosylation and the CD19-CAR T-cell efficacy and persistence in vivo. However, glycoengineered enforced sialofucosylation of E-selectin ligands was dispensable for CD19-CAR T-cell activity and BM homing in multiple xenograft models regardless the cytokines employed for T-cell expansion, thus, representing a dispensable strategy for CD19-CAR T-cell therapy. Glyco-engineered enforced sialofucosylation of E-selectin ligands was dispensable for CD19-CAR T-cell activity and BM homing in multiple xenograft models, thus representing an unnecessary strategy for CD19-CAR T-cell therapy
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Engraftment characterization of risk-stratified AML in NSGS mice

  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Molina, Oscar|||0000-0001-7585-4519
  • Nombela-Arrieta, Cesar|||0000-0003-0415-259X
  • Bataller, Alex|||0000-0002-6085-2745
  • Fuster, José Luis|||0000-0002-4881-9440
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gomez Casares, Maria Teresa|||0000-0003-0505-5126
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Lapillonne, Hélène|||0000-0002-6900-8313
  • Ramos-Mejía, Verónica|||0000-0002-8013-4273
  • Rodríguez-Manzaneque, Juan Carlos|||0000-0001-5951-7029
  • Bueno, Clara|||0000-0003-1442-6216
  • López-Millán, Belén|||0000-0002-9757-5454
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Disease heterogeneity is well documented, and patient stratification determines treatment decisions. Patient-derived xenografts (PDXs) from risk-stratified AML are crucial for studying AML biology and testing novel therapeutics. Despite recent advances in PDX modeling of AML, reproducible engraftment of human AML is primarily limited to high-risk (HR) cases, with inconsistent or very protracted engraftment observed for favorable-risk (FR) and intermediate-risk (IR) patients. We used NSGS mice to characterize the engraftment robustness/kinetics of 28 AML patient samples grouped according to molecular/ cytogenetic classification and assessed whether the orthotopic coadministration of patientmatched bone marrow mesenchymal stromal cells (BM MSCs) improves AML engraftment. PDX event-free survival correlated well with the predictable prognosis of risk-stratified AML patients. The majority (85-94%) of the mice were engrafted in bone marrow (BM) independently of the risk group, although HR AML patients showed engraftment levels that were significantly superior to those of FR or IR AML patients. Importantly, the engraftment levels observed in NSGS mice by week 6 remained stable over time. Serial transplantation and long-term culture-initiating cell (LTC-IC) assays revealed long-term engraftment limited to HR AML patients, fitter leukemia-initiating cells (LICs) in HR AML samples, and the presence of AML LICs in the CD342 leukemic fraction, regardless of the risk group. Finally, orthotopic coadministration of patient-matched BM MSCs and AML cells was dispensable for BM engraftment levels but favored peripheralization of engrafted AML cells. This comprehensive characterization of human AML engraftment in NSGS mice offers a valuable platform for in vivo testing of targeted therapies in risk-stratified AML patient samples.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Closa, Adria|||0000-0002-9302-337X
  • Martínez Moreno, Alba|||0000-0001-7514-260X
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Molina, Oscar|||0000-0001-7585-4519
  • Rodríguez-Cortez, Virginia Carolina|||0000-0002-0853-247X
  • Ximeno-Parpal, Pau|||0000-0003-1814-9607
  • Fernández Fuentes, Narcís|||0000-0002-6421-1080
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Beneyto Calabuig, Sergi|||0000-0003-3773-8239
  • Velten, Lars
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Casquero, Raquel
  • Abollo-Jiménez, Fernando
  • de la Guardia, Rafael D.
  • Lorden, Patricia
  • Bataller, Alex|||0000-0002-6085-2745
  • Lapillonne, Hélène|||0000-0002-6900-8313
  • Stam, Ronald W.
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Torrebadell, Montserrat
  • Fuster, José Luis|||0000-0002-4881-9440
  • Bueno, Clara|||0000-0003-1442-6216
  • Sarry, Jean Emmanuel
  • Eyras, Eduardo|||0000-0003-0793-6218
  • Heyn, Holger|||0000-0002-3276-1889
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIF and HIF specific AML subgroups (inv(16)/t(8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups. The HIF/hypoxia pathway signature is attenuated in AML-LSCs compared with more differentiated AML cells but is more expressed than in healthy hematopoietic cells. Importantly, chemical inhibition of HIF cooperates with standard-of-care chemotherapy to impair AML growth and to substantially eliminate AML-LSCs in vitro and in vivo. These findings support the HIF pathway in the stem cell-driven drug resistance of AML and unravel avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs.